WO1998045328A3 - Compositions and methods for the treatment and diagnosis of breast cancer - Google Patents

Compositions and methods for the treatment and diagnosis of breast cancer Download PDF

Info

Publication number
WO1998045328A3
WO1998045328A3 PCT/US1998/006939 US9806939W WO9845328A3 WO 1998045328 A3 WO1998045328 A3 WO 1998045328A3 US 9806939 W US9806939 W US 9806939W WO 9845328 A3 WO9845328 A3 WO 9845328A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
compositions
treatment
methods
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/006939
Other languages
French (fr)
Other versions
WO1998045328A2 (en
Inventor
Tony N Frudakis
John M Smith
Steven G Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/991,789 external-priority patent/US6225054B1/en
Priority to BR9808509-3A priority Critical patent/BR9808509A/en
Priority to EP98915351A priority patent/EP0975666A2/en
Priority to JP54305998A priority patent/JP4270523B2/en
Priority to AU69560/98A priority patent/AU6956098A/en
Priority to IL13228798A priority patent/IL132287A0/en
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to CA002286348A priority patent/CA2286348A1/en
Publication of WO1998045328A2 publication Critical patent/WO1998045328A2/en
Publication of WO1998045328A3 publication Critical patent/WO1998045328A3/en
Priority to NO994932A priority patent/NO994932L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by such nucleotide sequences. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer patient.
PCT/US1998/006939 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer Ceased WO1998045328A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002286348A CA2286348A1 (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
EP98915351A EP0975666A2 (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
JP54305998A JP4270523B2 (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
AU69560/98A AU6956098A (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
IL13228798A IL132287A0 (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
BR9808509-3A BR9808509A (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer
NO994932A NO994932L (en) 1997-04-09 1999-10-08 Mixtures and Methods for Treating and Diagnosing Breast Cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83876297A 1997-04-09 1997-04-09
US08/838,762 1997-04-09
US08/991,789 1997-12-11
US08/991,789 US6225054B1 (en) 1996-01-11 1997-12-11 Compositions and methods for the treatment and diagnosis of breast cancer

Publications (2)

Publication Number Publication Date
WO1998045328A2 WO1998045328A2 (en) 1998-10-15
WO1998045328A3 true WO1998045328A3 (en) 1999-04-22

Family

ID=27126060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006939 Ceased WO1998045328A2 (en) 1997-04-09 1998-04-09 Compositions and methods for the treatment and diagnosis of breast cancer

Country Status (12)

Country Link
EP (3) EP1127893A2 (en)
JP (1) JP4270523B2 (en)
KR (1) KR20010006220A (en)
AU (1) AU6956098A (en)
BR (1) BR9808509A (en)
CA (1) CA2286348A1 (en)
IL (1) IL132287A0 (en)
NO (1) NO994932L (en)
PL (1) PL336349A1 (en)
TR (1) TR199903154T2 (en)
WO (1) WO1998045328A2 (en)
ZA (1) ZA982968B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6225054B1 (en) 1996-01-11 2001-05-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6586570B1 (en) 1996-01-11 2003-07-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6344550B1 (en) 1996-01-11 2002-02-05 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US20020068285A1 (en) * 1996-01-11 2002-06-06 Frudakis Tony N. Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
NZ514646A (en) * 1999-04-09 2005-04-29 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
AU2004218695B2 (en) * 1999-04-09 2008-05-08 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1666494A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004505611A (en) * 2000-04-03 2004-02-26 コリクサ　コーポレイション Methods, compositions, and kits for breast cancer detection and monitoring
DK1889630T3 (en) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vaccines comprising MAGE antigen coupled to protein D fragment
EP1425302A2 (en) * 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002062A2 (en) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. C-erbb-2 external domain: gp75
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
WO1995032311A1 (en) * 1994-05-23 1995-11-30 Calypte, Inc. Non-hiv antibodies as disease markers
WO1996038463A1 (en) * 1995-05-31 1996-12-05 Washington University Dna sequence and encoded mammary-specific breast cancer protein
WO1997006256A2 (en) * 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997025426A2 (en) * 1996-01-11 1997-07-17 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
WO1997025431A1 (en) * 1996-01-10 1997-07-17 Corixa Corporation Compositions and methods for the treatment and diagnosis of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002062A2 (en) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. C-erbb-2 external domain: gp75
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
WO1995032311A1 (en) * 1994-05-23 1995-11-30 Calypte, Inc. Non-hiv antibodies as disease markers
WO1996038463A1 (en) * 1995-05-31 1996-12-05 Washington University Dna sequence and encoded mammary-specific breast cancer protein
WO1997006256A2 (en) * 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997025431A1 (en) * 1996-01-10 1997-07-17 Corixa Corporation Compositions and methods for the treatment and diagnosis of cancer
WO1997025426A2 (en) * 1996-01-11 1997-07-17 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BYRNE J A ET AL: "A SCREENING METHOD TO IDENTIFY GENE COMMONLY OVEREXPRESSED IN CARCINOMAS AND THE IDENTIFICATION OF A NOVEL COMPLEMENTARY DNA SEQUENCE", CANCER RESEARCH, vol. 55, no. 13, 1 July 1995 (1995-07-01), pages 2896 - 2903, XP002025781 *
LEIB-MOESCH C ET AL: "EVOLUTION AND BIOLOGICAL SIGNIFICANCE OF HUMAN RETROELEMENTS", VIRUS GENES, vol. 11, no. 2/03, 1996, pages 133 - 145, XP000673508 *
WATSON M A ET AL: "ISOLATION OF DIFFERENTIALLY EXPRESSED SEQUENCE TAGS FROM HUMAN BREAST CANCER", CANCER RESEARCH, vol. 54, no. 17, 1 September 1994 (1994-09-01), pages 4598 - 4602, XP000576043 *
WERNER T ET AL: "S71 IS A PHYLOGENETICALLY DISTINCT HUMAN ENDOGENOUS RETROVIRAL ELEMENT WITH STRUCTURAL AND SEQUENCE HOMOLOGY TO SIMIAN SARCOMA VIRUS (SSV)", VIROLOGY, vol. 174, no. 1, January 1990 (1990-01-01), pages 225 - 238, XP000670325 *
ZEHAN CHEN ET AL: "DIFFERENTIAL EXPRESSION OF HUMAN TISSUE FACTOR IN NORMAL MAMMARY EPITHELIAL CELLS AND IN CARCINOMAS", MOLECULAR MEDICINE, vol. 1, no. 2, January 1995 (1995-01-01), pages 153 - 160, XP000607858 *

Also Published As

Publication number Publication date
PL336349A1 (en) 2000-06-19
BR9808509A (en) 2001-09-18
EP1964850A3 (en) 2012-06-20
ZA982968B (en) 1998-10-27
JP4270523B2 (en) 2009-06-03
CA2286348A1 (en) 1998-10-15
AU6956098A (en) 1998-10-30
NO994932D0 (en) 1999-10-08
IL132287A0 (en) 2001-03-19
JP2001521384A (en) 2001-11-06
KR20010006220A (en) 2001-01-26
EP1127893A2 (en) 2001-08-29
TR199903154T2 (en) 2000-08-21
WO1998045328A2 (en) 1998-10-15
EP1964850A2 (en) 2008-09-03
EP0975666A2 (en) 2000-02-02
NO994932L (en) 1999-12-07

Similar Documents

Publication Publication Date Title
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP1964850A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
HUP0203035A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000055180A3 (en) Human lung cancer associated gene sequences and polypeptides
WO2003087831A3 (en) Proteins involved in breast cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ATE514780T1 (en) COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER AND USE THEREOF
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
WO2002062203A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO1999054466A3 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 132287

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2286348

Country of ref document: CA

Ref document number: 2286348

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-3550

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/009237

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019997009300

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 543059

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 500289

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 69560/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998915351

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1999/03154

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1998915351

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997009300

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1999-3550

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019997009300

Country of ref document: KR